

The Silent Crisis: Restoring Hearing, Advancing Healthy Aging

Building the world's first precision medicines to reverse hearing loss
— and stop dementia before it starts.



The World's Most Neglected Epidemic



1.6 billion people live with hearing loss – 1 in 4 by 2050

Driven by global aging and noise exposure




#1 Modifiable risk Factor for cognitive decline

Larger than hypertension, physical inactivity, or smoking combined



Zero drugs are approved to treat it

The Hearing Loss Field Wasn't Failing – It Was Missing the Tools



Cilcare is strategically positioned for leadership in a high-growth market

THERAPEUTICS



DATA – STRATIFICATION TOOLS



Lilly & Regeneron on congenital & genetic forms only

Most Biotech on niche markets

Cilcare on the most predominant, acquired and progressive, billions affected


Major tech players :

- raising awareness
- identify the problem


They accelerate the Market Access for Cilcare's drugs to fix the problem



From Founding to Global Partnership : Cilcare's 3-step Strategy




A broad drug pipeline with unique digital auditory markers for precision development


In-licensed from	Compounds	Indications	Discovery/ Portfolio evaluation	In vivo POC	Preclinical + Phase I Safety/CMC package	Phase IIa
sanofi	CIL001	Treatment of Synaptopathy in Type 2 Diabetes & Neurodegenerative diseases				SHIONOGI
sanofi	CIL001	Treatment of Synaptopathy in Tinnitus				SHIONOGI
sanofi	CIL003	Noise-induced Hearing Loss				SHIONOGI
Undisclosed	CIL005	Undisclosed Inflammation	New	On-going strategy for pipeline extension with new compounds' in-licensing & co-development		
Undisclosed	CIL006	Undisclosed Oxydation				
Undisclosed	CIL006	Undisclosed Rare disease				
Undisclosed	CIL007/8	Undisclosed Rare disease				
Asset	Auditory biomarkers Digital Auditory Signatures (DAS)		Data collection/ Phase 0	Validation		
 Synapsound - AI AI	DAS/Type 2 Diabetes		DIAMANT Phase 0 trial			
	DAS/Early Alzheimer		SAPHIR Phase 0 trial			
	DAS/Parkinson		SAPHIR Phase 0 trial			
	DAS/Autoimmune Diseases		RUBIS Phase 0 trial			

CIL001 : Focusing on the early stage of age-related hearing loss : Cochlear Synaptopathy

"We are potentially all affected at some point in our lives."



Cochlear synaptopathy : loss or dysfunction of synapses connecting inner hair cells to auditory nerve fibers, leading to **"hidden hearing loss"** — **difficulties hearing in noisy environments**, often without changes in standard audiograms.




Cochlear synaptopathy corresponds to the **first signs of hearing loss** and is often linked to **tinnitus, hyperacusis, and fatigue**.


CIL001 restores Synaptic Connections at the source to treat the early stage of age-related hearing loss

CIL001 is a small molecule that **stimulates neurotrophin secretion**, restoring synaptic connections between inner hair cells and auditory nerve fibers — directly treating cochlear synaptopathy.


- **Full preclinical package (Sanofi + Cilcare)**
- **Unprecedented efficacy on validated model**
- **Full Safety Package including Human Safety**
- **Protected until 2042**



**35 DAYS AFTER CIL001
SINGLE ADMINISTRATION (post trauma)**



CIL001 clinical strategy is unique : focus on 3 subpopulations of patients with high prevalence of cochlear synaptopathy



Critical for Clinical Development:

- Clear patient population
- Validated clinical endpoints
- Feasible recruitment
- Clear targeted labeling (indication)

Cilcare's translational strategy at the core of success.

The Team That Built What No One Else Could



Celia BELLINE, MS

Co-Founder &
Chief Executive Officer

Built Cilcare from Inception to
Shionogi partnership. Raised
multiple financing rounds



Jérôme GEOFFROY, MS

Chief Financial Officer &
Digital Strategy

IPO Affluent Medical on Euronext.
Raised multiple financing rounds



Gaëlle NAERT, PhD

Chief Scientific &
Operations Officer

Pioneered Cochlear Synaptopathy
models. 20+ years in Neuroscience



Patricia MACHADO, PhD, MBA

Early Drug Development &
Pipeline Director

10+ years of Research Alliance and
drug scouting in major Pharma



Mathieu SCHUE, PhD

Chief Clinical Operations Officer



Louis DELAMARRE, MD, PhD

Director Translational Research



Marie-Pierre PASDELOU, Pharm. D

Co-Founder &
Chief Compliance Officer **PLAVIX,**
IRBESARTAN, ARIXTRA, FRAXIPARIN



Bettina COCKROFT, MD

Chief Medical Officer



Sylvie PUCHEU, Ph.D.

Co-Founder &
Director of Preclinical Innovation



Hugo LAULLIER, MS

Head of Data & AI



Camille ROCHMANN, Pharm. D

Evidence, Value & Access
Senior Manager **DUPIXENT**



Aurore MARIE, MS

Director of Alliance Management

Independent Board Members



Preethi SUNDARAM, PhD

Independent Board Member
Chief Strategic Officer, Catalyst



Christophe DOUAT, MS

Independent Board Member
CEO, MedinCell



A Network of Strategic Partners and a transatlantic operational footprint



Sanofi

Early-stage co-development partner that provided the scientific foundation from which CIL001 and CIL003 were later in-licensed. A critical validation of the drug pipeline's origins.



CBSET

US-based preclinical research organization development and validating Cilcare's transatlantic scientific presence from early stages.



KOL Network Worldwide

Academic and clinical partners providing access to patient populations worldwide and expertise, anchoring Cilcare's US/EU clinical strategy ahead of IND/CTA submissions.



Shionogi

Top-5 Japan pharmaceutical group and lead investor in the Series A. License partner for worldwide rights to CIL001 and CIL003, providing both capital and operational development power.





The Future We're Building

**In 10 years, hearing loss will be
treated like heart disease.**

Diagnosed early. Treated effectively. No longer accepted as inevitable.

*"We're inviting you to join us in building
the defining company in hearing therapeutics."*

